Research institution
Guangdong Provincial People's Hospital Clinical Trials
Studies where Guangdong Provincial People's Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 79NSCLC (Non-small Cell Lung Cancer)
D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
This study is a single-arm prospective single-center phase II study. Subjects are untreated resectable stage II-IIIA or potentially resectable T3-4N2 stage IIIB NSCLC.
- Trial name
- NCT07016126
- Testing
- D-BACE in combination with chemotherapy and karelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Guangdong Provincial People's Hospital
Lung Cancer (NSCLC), KRAS G12C Lung Cancer
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib…
- Trial name
- GIVEN (NCT07472478)
- Testing
- Garsorasib, Ivonescimab Combined With Chemotherapy, Surgery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.
- Conditions
- Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Paclitaxel-induced Peripheral Neuropathy
- Trial name
- NCT07410169
- Testing
- Hyperbaric oxygen treatment, Standard Care (in control arm)
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
NSCLC (Non-small Cell Lung Carcinoma)
Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
This study explores the difference in progression-free survival (PFS) between local consolidative therapy (LCT arm) targeting residual lesions and continued systemic therapy (non-LCT arm) in patients with metastatic NSCLC who…
- Trial name
- NCT07842471
- Testing
- Immediate Local Consolidative Therapy (LCT)
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Guangdong Provincial People's Hospital
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
- Trial name
- BOND-4 (NCT07722754)
- Testing
- Cetuximab, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Adverse Event, Peritoneal Dialysis
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
Moderate to severe pruritus significantly impairs the quality of life in peritoneal dialysis patients, and effective treatment options remain limited.
- Conditions
- Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch
- Trial name
- KARE-PD (NCT07098351)
- Testing
- Remitch
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy
Correlation of Microbiome and Metabonomics With IgA Nephropathy
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium.
- Trial name
- NCT05190848
- Where
- 5 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
This is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which ST-segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(TIMI thrombus grade ≥3) are included.
- Trial name
- NCT04212494
- Testing
- Thrombus aspiration, PCI Alone
- Where
- 50 sites in China
- Volunteers
- 3,838 people
- Sponsor
- Guangdong Provincial People's Hospital
Obsessive Compulsive Disorder (OCD)
The Effects and Neural Mechanisms of Vitamin D and Iron-Immune Homeostasis on Inhibitory Control in Obsessive-Compulsive Disorder
This study is a randomized, open-labled, no-treatment-controlled clinical trial designed to investigate the effects of vitamin D and iron-immune homeostasis on inhibitory control and the underlying neural mechanisms in patients…
- Trial name
- NCT07763977
- Testing
- Calcitriol and Iron Supplements
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
This is an investigator initiated, single-arm, open-label, dose-escalation study to explore the preliminary efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the universal STAR-T…
- Trial name
- NCT07746453
- Testing
- Universal STAR-T Cell
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangdong Provincial People's Hospital